Contact this trialFirst, we need to learn more about you.
Tildacerfont for Congenital Adrenal Hyperplasia
Recruiting0 awardsPhase 2
Reno, Nevada
This trial looks at whether Tildacerfont can help reduce the amount of glucocorticoid drugs needed to treat people with classic Congenital Adrenal Hyperplasia. The trial will last up to 76 weeks, with an optional extension up to 240 weeks.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.